Novartis Ends PDI Contract
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis is terminating its contract sales investment with PDI for Diovan and Lotrel
You may also be interested in...
AstraZeneca To Save $60 Mil. Through PDI Sales Rep Reduction
No cuts will be made to the in-house sales force, AstraZeneca says. The company maintains that the decision was not in response to Exanta "not approvable" letter or the halt in Iressa promotions.
AstraZeneca To Save $60 Mil. Through PDI Sales Rep Reduction
No cuts will be made to the in-house sales force, AstraZeneca says. The company maintains that the decision was not in response to Exanta "not approvable" letter or the halt in Iressa promotions.
PDI Growth Strategy Includes Acquisition Of Complementary Businesses
The company will also focus on organic growth through “aggressive business development” and introduction of new services, CEO Saldarini says. PDI expects that manufacturers will embrace outsourcing a larger portion of their sales force for maximum flexibility.